Snehal has a confluence of regulatory affairs, early discovery, innovation, policy, and scientific expertise across 15 years in the pharmaceutical and biotech industry. At Spark, she established the regulatory policy function and is supporting global development of gene therapies. In keeping with her keen interest in influencing gene therapy policy and shaping the regulatory framework for advanced therapies, Snehal co-chairs the regenerative medicine committee at BIO and staffs the regulatory affairs committees of the American Society of Gene & Cell Therapy and the Bespoke Gene Therapy Consortium, along with efforts at the Alliance for Regenerative Medicine and the Innovative Medicines Initiative. With a penchant for exploring the unexplored, she has led biology programs at both Pfizer’s Centers for Therapeutic Innovation and Johnson & Johnson’s Janssen Incubator, and founded and led a cross-functional gene therapy community of practice at JnJ. Snehal graduated summa cum laude with an AB-MA in Biology from Bryn Mawr College, and holds a Ph.D. in Molecular Genetics and Genomics from Washington University in St. Louis where she also completed the Cancer Biology pathway with the Siteman Cancer Center.